| Literature DB >> 35511463 |
Calista Leung1, Julia Pei1, Kristen Hudec1, Farhud Shams1, Richard Munthali1, Daniel Vigo1.
Abstract
BACKGROUND: Digital mental health interventions are increasingly prevalent in the current context of rapidly evolving technology, and research indicates that they yield effectiveness outcomes comparable to in-person treatment. Integrating professionals (ie, psychologists and physicians) into digital mental health interventions has become common, and the inclusion of guidance within programs can increase adherence to interventions. However, employing professionals to enhance mental health programs may undermine the scalability of digital interventions. Therefore, delegating guidance tasks to paraprofessionals (peer supporters, technicians, lay counsellors, or other nonclinicians) can help reduce costs and increase accessibility.Entities:
Keywords: digital health; digital health intervention; digital mental health; e-Mental health intervention; internet-based intervention; mental health; nonclinician guidance; patient outcome; task shifting
Mesh:
Year: 2022 PMID: 35511463 PMCID: PMC9244656 DOI: 10.2196/36004
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 7.076
Figure 1PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart.
Summary of results.
| Study, year | Results | ||
|
| |||
|
| Targeted disorder | Substance use (smoking) | |
|
| Subjects for each study condition, n | Nonclinician, 456; unguided, 473; control; 476 | |
|
| Effectiveness outcome (30-day smoking abstinence), % | Nonclinician, 14%; unguided, 11%; control, 9% | |
|
| |||
|
| Targeted disorder | Depression | |
|
| Subjects for each study condition, n | Nonclinician, 159; control, 154 | |
|
| Effectiveness outcome (Patient Health Questionnaire-9 score), mean (SD) | Nonclinician, 8.5 (5.74); control, 10.83 (6.21) | |
|
| |||
|
| Targeted disorder | Depression | |
|
| Subjects for each study condition, n | Nonclinician, 33; control (delayed access), 33 | |
|
| Effectiveness outcome (Depression, Anxiety and Stress Scale depression score), mean (SD) | Nonclinician, 10.43 (4.49); control, 14.6 (9.51) | |
|
| Adherence outcome (completion of all modules), % | Nonclinician, 61%; control, N/Aa (adherence outcomes unreported) | |
|
| Process outcome | Usefulness | |
|
| Results | The average usefulness rating of the overall modules was 6.78/10 (ranging from 1, “not useful at all,” to 10, “extremely useful”). | |
|
| |||
|
| Targeted disorder | Depression | |
|
| Subjects for each study condition, n | Nonclinician, 41; unguided, 42 | |
|
| Effectiveness outcome (Patient Health Questionnaire-9 score), mean (SD) | Nonclinician, 4.83 (2.7); unguided, 5.51 (4.5) | |
|
| Adherence outcome (completion of all modules), % | Nonclinician, 93%; unguided, 81% | |
|
| Process outcome | Satisfaction | |
|
| Results | A total of 85% of unguided and 90% of nonclinician-guided participants were either “satisfied” or “very satisfied” with the course (no significant difference), 93% of unguided and 100% of nonclinician-guided participants were either “satisfied” or “very satisfied” with the quality of the lessons and the materials (no significant difference); nonclinician-guided participants had significantly higher levels of satisfaction with the level of support, though both groups had relatively high satisfaction (96% of participants overall were “satisfied” or “very satisfied”). | |
|
| |||
|
| Targeted disorder | Depression | |
|
| Subjects for each study condition, n | Nonclinician, 41; unguided, 38; control, 35 | |
|
| Effectiveness outcome (Center for Epidemiologic Studies Depression Scale score), mean (SD) | Nonclinician, 21 (12.4); unguided, 24.4 (13.6); control, 35.1 (13.9) | |
|
| Adherence outcome (minimum dose: 3/5 modules), % | Nonclinician, 37.7%; unguided, 31.6%; control, N/A (received no intervention) | |
|
| Adherence outcome (completion of all modules), % | Nonclinician, 17.8%; unguided, 15.8%; control, N/A (received no intervention) | |
|
| |||
|
| Targeted disorder | Mental well-being | |
|
| Subjects for each study condition, n | Nonclinician, 30; unguided, 30 | |
|
| Effectiveness outcome (Warwick-Edinburgh Mental Wellbeing Scale score), mean (SD) | Nonclinician, 48.43 (12.66); unguided, 42.88 (9.66) | |
|
| Adherence outcome (completion of all modules), % | Nonclinician, 52%; unguided, 43% | |
|
| |||
|
| Targeted disorder | Stress | |
|
| Subjects for each study condition, n | Nonclinician, 132; control (delayed access), 132 | |
|
| Effectiveness outcome (Perceived Stress Scale-10 score), mean (SD) | Nonclinician, 17.88 (6.17); control, 22.96 (6.07) | |
|
| Adherence outcome (completion of all modules), % | Nonclinician, 70.5%; control, N/A (adherence outcomes unreported) | |
|
| Process outcome | Satisfaction | |
|
| Results | A total of 92.2% of participants were “satisfied in an overall, general sense” (ie, either “very satisfied” or “mostly satisfied”). | |
|
| |||
|
| Targeted disorder | Obsessive compulsive disorder | |
|
| Subjects for each study condition, n | Clinician, 31; nonclinician, 28; unguided, 28 | |
|
| Effectiveness outcome (Yale Brown Obsessive Compulsive Scale score), mean (SD) | Clinician, 15.32 (7.04); nonclinician, 15.61 (5.88); unguided, 16.32 (6.97) | |
|
| Process outcomes | Satisfaction, usability | |
|
| Results | A total of 98% of participants “agreed” or “strongly agreed” with the statement that “they were satisfied with bt steps.” For usability, the mean total system usability score was 83.5/100 (between “good” and “excellent”). | |
|
| |||
|
| Targeted disorder | Posttraumatic stress disorder and hazardous drinking | |
|
| Subjects for each study condition, n | Nonclinician, 15; unguided, 15 | |
|
| Effectiveness outcome (Posttraumatic Stress Disorder Checklist—Military score), mean (SD) | Nonclinician, 41.78 (14.90); unguided, 43.16 (13.42) | |
|
| Process outcome | Satisfaction | |
|
| Results | A total of 78% of participants were “very satisfied.” | |
|
| |||
|
| Targeted disorder | Bipolar disorder (perception of illness) | |
|
| Subjects for each study condition, n | Nonclinician, 139; unguided, 141; control, 139 | |
|
| Adherence outcome (minimum dose; 4/8 module workbooks) | Nonclinician, 79.9%; unguided, 69.1%; control, N/A (received no intervention) | |
|
| Adherence outcome (completion of all modules) | 38.8% across 3 groups | |
|
| |||
|
| Targeted disorder | Generalized anxiety disorder | |
|
| Subjects for each study condition, n | Clinician, 47; nonclinician, 50; control (delayed access), 48 | |
|
| Effectiveness outcome (General Anxiety Disorder-7 score), mean (SD) | Clinician, 5.55 (4.73); nonclinician, 6.02 (3.43); control, 11.25 (4.70) | |
|
| Adherence outcome (completion of all modules), % | Clinician, 74%, nonclinician, 80%; control, N/A (received no intervention) | |
|
| Process outcome | Satisfaction | |
|
| Results | A total of 87% of participants in the nonclinician-guided and clinician-guided groups were either “very satisfied” or “mostly satisfied” with the overall program (no significant difference). | |
|
| |||
|
| Targeted disorder | Depression | |
|
| Subjects for each study condition, n | Nonclinician, 37; control, 40 | |
|
| Effectiveness outcome (Hamilton Depression Rating Scale-17 score), mean (SD) | Nonclinician, 9.17 (6.92), control, 14.05 (5.34) | |
|
| Adherence outcome (completion of all modules), % | Nonclinician, 92%; control, 75% | |
|
| |||
|
| Targeted disorder | Depression | |
|
| Subjects for each study condition, n | Clinician, 46; nonclinician, 41; control, 40 | |
|
| Effectiveness outcome (Beck Depression Inventory-II score), mean (SD) | Clinician, 14.59 (11.12); nonclinician, 15.29 (9.81); control, 26.15 (10.14) | |
|
| Adherence outcome (completion of all modules), % | Clinician, 80%; nonclinician, 80%; control, N/A (adherence outcomes unreported) | |
|
| Process outcome | Satisfaction | |
|
| Results | A total of 87% of participants in the nonclinician-guided or clinician-guided groups were either “very satisfied” or “mostly satisfied” with the overall program (no significant difference). | |
aN/A: not applicable.
bPossemato reported a nonclinician intervention retention rate of 93% and unguided intervention retention rate of 73% but did not define “intervention retention.”
Cochrane risk-of-bias tool version 2 summary.
| Study, year | Randomization process | Deviations from intended interventions | Missing outcome data | Measurement of the outcome | Selection of the reported result | Overall | |||||||
|
| |||||||||||||
|
| An et al, 2013 [ | Low | Some concerns | High | Some concerns | High | High | ||||||
|
| Arjadi et al, 2018 [ | Low | Low | Low | Low | Low | Low | ||||||
|
| Day et al, 2013 [ | Low | Low | Low | Low | Some concerns | Some concerns | ||||||
|
| Dirkse et al, 2020 [ | Low | Low | Low | Low | Some concerns | Some concerns | ||||||
|
| Farrer et al, 2011 [ | Some concerns | Low | Low | Low | High | High | ||||||
|
| Flynn et al, 2020 [ | Low | High | High | Low | Some concerns | High | ||||||
|
| Heber et al, 2016 [ | Low | Low | Low | Low | Some concerns | Some concerns | ||||||
|
| Kobak et al, 2015 [ | Some concerns | High | Low | Low | Some concerns | High | ||||||
|
| Possemato et al, 2019 [ | Low | Low | Low | Some concerns | Some concerns | Some concerns | ||||||
|
| Robinson et al, 2010 [ | Some concerns | Low | Low | Some concerns | Low | Some concerns | ||||||
|
| Rosso et al, 2017 [ | Low | Low | Low | Low | Some concerns | Some concerns | ||||||
|
| Titov et al, 2010 [ | Some concerns | Low | High | Low | Some concerns | High | ||||||
|
| |||||||||||||
|
| Day et al, 2013 [ | Low | Low | Low | Low | Low | Low | ||||||
|
| Dirkse et al, 2020 [ | Some concerns | Low | Low | Low | Low | Some concerns | ||||||
|
| Farrer et al, 2011 [ | Some concerns | Low | Low | Low | Low | Some concerns | ||||||
|
| Flynn et al, 2020 [ | Low | High | Low | Low | Low | High | ||||||
|
| Heber et al, 2016 [ | Low | Some concerns | Low | Low | Low | Some | ||||||
|
| Proudfoot et al, 2012 [ | Low | Low | Low | Low | High | High | ||||||
|
| Robinson et al, 2010 [ | Some concerns | Low | Low | Low | Low | Some concerns | ||||||
|
| Rosso et al, 2017 [ | Low | Low | Low | Low | Low | Low | ||||||
|
| Titov et al, 2010 [ | Some concerns | Low | Low | Low | Low | Some concerns | ||||||
|
| |||||||||||||
|
| An et al, 2013 [ | Low | Some concerns | Low | Low | Low | Some concerns | ||||||
|
| Farrer et al, 2011 [ | Some concerns | Low | Low | Low | Low | Some concerns | ||||||
|
| Proudfoot et al, 2012 [ | Low | Low | Low | Low | High | High | ||||||
|
| |||||||||||||
|
| Arjadi et al, 2018 [ | Low | Low | Low | Low | Low | Low | ||||||
|
| Farrer et al, 2011 [ | Some concerns | Low | Low | Low | Low | Some concerns | ||||||
|
| |||||||||||||
|
| Possemato et al, 2019 [ | Low | Low | Low | Low | Some concerns | Some concerns | ||||||
|
| |||||||||||||
|
| Day et al, 2013 [ | Low | Low | High | High | Low | High | ||||||
|
| Dirkse et al, 2020 [ | Low | Low | Low | High | Some concerns | High | ||||||
|
| Heber et al, 2016 [ | Low | Some concerns | High | Low | Low | High | ||||||
|
| Kobak et al, 2015 [ | Some concerns | High | Low | Some concerns | Some concerns | High | ||||||
|
| Possemato et al, 2019 [ | Low | Low | High | High | Low | High | ||||||
|
| Robinson et al, 2010 [ | Some concerns | Low | High | Low | Low | High | ||||||
|
| Titov et al, 2010 [ | Some concerns | Low | High | High | Some concerns | High | ||||||
Figure 2Nonclinician versus clinician, posttreatment. SMD: standardized mean difference.
Figure 3Nonclinician versus unguided, posttreatment. SMD: standardized mean difference.
Figure 4Nonclinician versus control, posttreatment. SMD: standardized mean difference.
Figure 5Nonclinician versus unguided, follow up. SMD: standardized mean difference.
Figure 6Nonclinician versus control, follow up.
Figure 7Adherence outcomes. OR: odds ratio.